Franz Hefti Net Worth

Franz Hefti biography

Dr. Franz F. Hefti Ph.D. serves as Chief Development Officer of the Company. Prior to joining us, he was Chief Operations Officer at Proclara Biosciences, Inc., a biotechnology company, from June 2014 to December 2017. Prior to this, he served as President and Chief Executive Officer of Acumen Pharmaceuticals, Inc. from November 2011 to January 2015. Previously, Dr. Hefti served as Chief Scientific Officer at Avid Radiopharmaceuticals, Inc., a pharmaceutical company acquired by Eli Lilly and Company, Executive Vice President of Drug Development at Rinat Neuroscience Corporation, a pharmaceutical company acquired by Pfizer Inc., Senior Vice President of Neuroscience Research at Merck & Co., Inc., or Merck, and Head of Neuroscience Research at Genentech, Inc., a biotechnology corporation acquired by F. Hoffmann-La Roche AG, or Roche. Dr. Hefti currently serves on the boards of directors of several private biotechnology companies, including Spinogenix, Inc., Sophren Inc., Cadent Therapeutics, Inc. and Proclara Biosciences Inc. He has also held positions as a Professor at the University of Southern California and as Associate Professor at the University of Miami, where he carried out discovery research on therapeutic approaches to neurodegenerative diseases. He has been a member of the Scientific Advisory Board of the Alzheimer’s Disease Imaging Initiative since 2013. Dr. Hefti received a Ph.D. in biology from the University of Zurich and completed his postdoctoral research at the Massachusetts Institute of Technology.

What is the salary of Franz Hefti?

As the Chief Development Officer of Prevail Therapeutics Inc, the total compensation of Franz Hefti at Prevail Therapeutics Inc is $1,063,810. There are 3 executives at Prevail Therapeutics Inc getting paid more, with Asa Abeliovich having the highest compensation of $2,861,680.

How old is Franz Hefti?

Franz Hefti is 72, he's been the Chief Development Officer of Prevail Therapeutics Inc since 2018. There are no older and 12 younger executives at Prevail Therapeutics Inc.

What's Franz Hefti's mailing address?

Franz's mailing address filed with the SEC is C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK, NY, 10016.

Insiders trading at Prevail Therapeutics Inc

Over the last 5 years, insiders at Prevail Therapeutics Inc have traded over $0 worth of Prevail Therapeutics Inc stock and bought 36,931,845 units worth $816,407,705 . The most active insiders traders include Acquisition Corp Eli Lilly ..., Peter A. Thompson, eAdvisors Llc Orbi Med Capit.... On average, Prevail Therapeutics Inc executives and independent directors trade stock every 96 days with the average trade being worth of $138,767,762. The most recent stock trade was executed by Acquisition Corp Eli Lilly ... on 22 January 2021, trading 34,284,789 units of PRVL stock currently worth $771,407,753.

What does Prevail Therapeutics Inc do?

Prevail Therapeutics Inc executives and stock owners

Prevail Therapeutics Inc executives and other stock owners filed with the SEC include:

• Asa Abeliovich,
  President, Chief Executive Officer, Director
• Jeffrey Sevigny,
  Chief Medical Officer
• Yong Dai,
  Chief Technology Officer
• Franz Hefti,
  Chief Development Officer
• Francois Nader,
  Independent Chairman of the Board
• Timothy Adams,
  Independent Director
• Morgan Sheng,
  Independent Director
• Ran Nussbaum,
  Independent Director
• Carl Gordon,
  Director
• Peter Thompson,
  Independent Director
• William Carson,
  Director
• Emily Minkow,
  Chief Business Officer
• Kira Schwartz,
  General Counsel
• Brett Kaplan,
  Chief Financial Officer
• Advisors Llc Orbi Med Capit...,
  
• Acquisition Corp Eli Lilly ...,